Hims & Hers Health stock soared 8.43% on Monday, extending a multi-day rally.

The surge is driven by significant regulatory and commercial catalysts. The U.S. FDA plans to remove 12 peptides from its restricted list and will convene an advisory panel to assess their production by compounding pharmacies, a move that could substantially expand Hims's market in metabolic health and anti-aging treatments. Concurrently, the company entered a partnership with pharmaceutical giant Novo Nordisk to sell weight-loss drugs directly on its platform, adding a major new revenue stream.